Responding to a GMP/GDP post inspection letter

AI Summary

This regulatory guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) details the standardized protocols for pharmaceutical companies when responding to deficiencies identified during Good Manufacturing Practice (GMP) or Good Distribution Practice (GDP) inspections. Although this document provides a general framework rather than addressing a specific company or inspection date, it outlines the strict expectations for remediating violations found during the inspection process. The guidance categorizes findings into Critical, Major, and Other deficiencies, frequently referencing the EU GMP regulatory framework. To ensure compliance, companies must provide responses in an editable Word document using a distinct color-coding system to differentiate between site replies and inspector requests. Key required actions include addressing systemic issues across the entire organization rather than isolated incidents, setting realistic deadlines in a specific DD/MM/YYYY format, and implementing interim safety measures for complex, long-term remediations to protect patient safety. Companies are instructed to remain concise, avoid submitting unnecessary evidence unless specifically requested, and provide clear descriptions of their internal system reviews. If an organization determines it cannot meet a previously agreed-upon deadline, they must proactively notify the inspector using an interim compliance report before the deadline expires. Adhering to this structured format is essential for the MHRA to reach a timely and favorable compliance decision regarding the site's operational status.